Protocol Ledger

NCT05219617 · Phase III · RECRUITING

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Interventional Phase III clinical trial protocol NCT05219617 sponsored by SK Life Science in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-28 Enrollment: 252 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05219617
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)252 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05219617
Protocol FieldVerified Registry Value
NCT IdentifierNCT05219617
Consolidated Lead SponsorSK Life Science
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment252 participants (ESTIMATED)
Registered Start Date2022-04-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05219617
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
University of South FloridaTampa, FLOpen Hospital Dossier ->
University Medical Center New OrleansNew Orleans, LAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI